Fig. 3: Association of TMB with treatment response. | npj Breast Cancer

Fig. 3: Association of TMB with treatment response.

From: Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy

Fig. 3

a TMB in responders and nonresponders. b AUROC analysis of the association between TMB and objective response rate. c Overall survival in participants with TMB ≥ 10 mut/Mb and participants with TMB < 10 mut/Mb. Median TMB was 3.78 mut/Mb among both responders and nonresponders in the pembrolizumab group; median TMB was 2.52 mut/Mb among responders in the chemotherapy group and 3.78 mut/Mb among responders in the chemotherapy group. In these boxplots, the whiskers extend no further than 1.5 times the interquartile range; dots represent values that fall outside 1.5 times the interquartile range. aResponders include participants who had a complete or partial response per RECIST version 1.1. AUROC area under the receiver operating characteristic curve, mut/Mb mutations per megabase, RECIST Response Evaluation Criteria in Solid Tumors, TMB tumor mutational burden.

Back to article page